Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Oncomedics is managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This single action is being reviewed by 1 distinct examiner within a single distinct art unit, indicating a concentrated effort on a specific application. This level of focus is common for companies targeting a particular biotechnological or pharmaceutical advancement.
The busiest examiner, WILLIAMS, EMMALEE RAE, is responsible for the pending action. With only the 1 pending office action in the portfolio, the company's current prosecution results are entirely dependent on the feedback and decisions of this examiner. Practitioners should carefully analyze the past decisions of the assigned examiner to tailor their arguments, as there are no other pending actions to balance the risks associated with a single point of review in the Biotechnology & Pharmaceuticals sector. The success of the company's current patent strategy relies on a favorable outcome for this matter within the 1 distinct art unit involved.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WILLIAMS, EMMALEE RAE | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18293557 | COMPOSITIONS AND METHODS FOR DECONTAMINATING AND CULTURING A GASTROINTESTINAL TRACT SAMPLE | WILLIAMS, EMMALEE RAE | — |
| Art Unit | Apps |
|---|---|
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18293557 | COMPOSITIONS AND METHODS FOR DECONTAMINATING AND CULTURING A GASTROINTESTINAL TRACT SAMPLE | WILLIAMS, EMMALEE RAE | 1653 | §103§112 | Non-Final OA | — | Pending | Jan 30, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOncomedics has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Emmalee Rae Williams has the most, with 1 of Oncomedics's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
